TW201822825A - System for Chemotherapy Delivery and Method of the Same - Google Patents

Abstract

A system for chemotherapy delivery comprises a plurality of slots to receive a corresponding one of a plurality of cartridges; a plurality of pumps, wherein each of the plurality of pumps is configured to be connected to the corresponding one of the plurality of cartridges, and the plurality of pumps are configured to pump at least one drug contained in at least one of the plurality of cartridges to a patient according to a treatment protocol; a blood glucose sensor communicatively coupled to the plurality of pumps, and configured to measure a blood glucose level of the patient; a processor connected to the plurality of pumps and the blood glucose sensor and configured to adjust a delivery property of the at least one drug according to the measured blood glucose level of the patient.

Description

Chemotherapy delivery system and method

The present disclosure relates to chemotherapy devices and, more particularly, to a Warburg effect targeted chemotherapy device.

Cancer is a metabolically altered disease, just as it is a disease of uncontrolled cell growth. The targeting of metabolic pathways in cancer cells has a long history, and many of the current chemotherapeutic drugs target some of these pathways. Recently, additional metabolic pathways have led to a targeted interest in the dependence of cancer on glucose supply. The metabolism of this change in cancer is best used in PET scanning technology, where the sensitivity rate is over 90%, making this altered metabolism almost a universal feature of cancer.

According to a first aspect of the present disclosure, a system for chemotherapy delivery, comprising a plurality of slots, wherein each of the plurality of slots is configured to receive a corresponding one of a plurality of cartridges; a plurality of pumps, wherein said plurality Each of the pumps is configured to be coupled to a respective one of the plurality of cartridges, and the plurality of pumps are configured to pump at least one drug contained in at least one of the plurality of cartridges according to a treatment regimen, wherein At least one drug comprises insulin, glucose, and at least one chemotherapeutic drug, and the plurality of cartridges are configured to contain insulin, glucose, and at least one chemotherapeutic drug, respectively; a blood glucose sensor communicatively coupled to the plurality of pumps, and configured to measure a blood glucose level of the patient; a processor coupled to the plurality of pumps and the blood glucose sensor, and configured to adjust a delivery characteristic of the at least one drug based on the measured blood glucose level of the patient; and wherein the plurality of pumps are further configured by the processor The pumping of at least one drug is adjusted based on the adjusted delivery characteristics.

In accordance with another aspect of the present disclosure, a method for chemotherapy delivery, comprising receiving a corresponding one of a plurality of cartridges by each of a plurality of slots; each connected to a corresponding one of the plurality of cartridges Pumping, according to a treatment protocol, pumping at least one drug contained in at least one of the plurality of cartridges, wherein the at least one drug comprises insulin, glucose, and at least one chemotherapeutic drug, and the plurality of cartridges are configured to contain insulin, respectively Glucose and at least one chemotherapeutic drug; a blood glucose sensor communicatively coupled to the plurality of pumps to measure blood glucose levels of the patient; by a processor coupled to the plurality of pumps and the blood glucose sensor, based on the measured blood glucose level of the patient Adjusting the delivery characteristics of the at least one drug; and adjusting the pumping of the at least one drug by the plurality of pumps in accordance with the adjusted delivery characteristics.

According to a third aspect of the present disclosure, a computer readable storage medium, when executed by a processor, causes a computer to perform operations of controlling each of a plurality of pumps connected to a corresponding one of the plurality of cartridges, according to The treatment protocol pumps at least one drug contained in at least one of the plurality of cartridges, wherein the at least one drug comprises insulin, glucose, and at least one chemotherapeutic drug, and the plurality of cartridges are configured to contain insulin, glucose, and at least one chemotherapy, respectively a blood glucose sensor communicatively coupled to the plurality of pumps to measure a blood glucose level of the patient; to adjust a delivery characteristic of the at least one drug based on the measured blood glucose level of the patient; and to control the plurality of pumps to adjust at least one of the adjusted delivery characteristics Pumping of the drug.

The embodiments set forth below represent the necessary information to enable those skilled in the art to practice the embodiments and the best mode of the embodiments. The following description is read in light of the accompanying drawings, and FIG. It should be understood that these concepts and applications fall within the scope of the disclosure and the appended claims.

The terminology used herein is for the purpose of describing the embodiments, Where the context allows, words in the singular or plural may also include the plural or singular, respectively.

As used herein, terms such as "processing," "calculating," "calculating," "determining," "displaying," "generating," and the like refer to a computer or similar electronic computing device, unless specifically stated otherwise. The following acts and processes that manipulate and convert data represented in the memory of a computer or within a register as a physical (electronic) quantity into other memory, registers or other such storage medium, transmission or display device, similarly represented as a computer The amount of physical data in the data.

As used herein, terms such as "connected," "coupled," etc. mean any direct or indirect connection or coupling between two or more elements. The coupling or connection between the elements can be physical, logical or a combination thereof. A reference to "an embodiment", "an embodiment" or the like in this specification means that a particular feature, function, structure or characteristic described is included in at least one embodiment of the present disclosure. The appearances of such phrases in the specification are not necessarily referring to the same embodiment. On the other hand, the embodiments mentioned are not necessarily mutually exclusive.

As used herein, terms such as "cause" and variations thereof refer to a direct causal relationship or an indirect causal relationship. For example, a computer system can "cause" an action by sending a message to a second computer system that requests or prompts the second computer system to perform an action. Any number of intermediate devices can check and/or relay the message during this process. In this regard, the device may "cause" an action even if the device may not know if the action will ultimately be performed.

Note that in the present description, any reference to a message, signal, etc. to another device (receiver device) means that the message is sent with the intent of its information content being ultimately delivered to the recipient device; therefore, Such a reference does not mean that the message must be sent directly to the recipient device. That is, unless otherwise stated, one or more intermediate entities may receive and forward the original content or receive and forward the message/signal in a modified form before it is transmitted to the recipient device. This description also applies to any reference herein to receiving a message/signal from another device; that is, no direct peer-to-peer communication is required unless otherwise stated.

As used herein, the term "or" can encompass all possible combinations unless otherwise indicated. For example, if the claim data can include A or B, the data can include A, or B, or A and B unless specifically stated or not feasible. As a second example, if the declared data may include A, B or C, the data may include A, or B, or C, or A and B, or A and C, or B unless otherwise specified or not feasible. And C, or A and B and C. Local glucose concentration in cancer tissues

A recent study in cancer research focused on different frozen metabolites in cancerous and normal tissues after surgery. The study found that glucose levels in cancerous tissues were 3 to 12 times lower than in normal tissues. (Hirayama et al., 2009) Cancer tissue has consumed glucose due to high glycolysis rates. This will necessarily be more pronounced in ischemic tissues with poor vascularization. Effect of glycolysis on drug resistance and redox status of cell survival

Cancer cells usually survive in an oxidative stress environment. Many cancer drugs work by an increase in oxidative stress. Apoptosis requires an oxidative state within the cell to trigger and initiate a cascade of reactions leading to cell death. Cancer cells are able to respond to oxidative stress and avoid apoptosis via glutathione, the main intracellular antioxidant, by reduction. (Vaughn et al., 2008) Reconstructing oxidized glutathione via glutathione reductase using NAPDH as an electron donor and generating NADP ⁺ . NADP ⁺ is converted to NAPDH in one of the two pathways of the pentose phosphate pathway, which metabolizes glucose. Another pathway, standard glycolysis, can be rapidly converted to the pentose phosphate pathway after the cells receive oxidative stress, such as by oxidative stress delivered by the drug. (Patra, et al., 2014)

Due to overexpression of glucose transporters and metabolic enzymes, cancer cells have a high capacity to metabolize glucose. This high level of glycolysis leads to a buffering effect on oxidative stress by reducing oxidized glutathione. Many cancer drugs carry drug-resistant drugs such as daunorubicin (Cao et al., 2007), doxorubicin and paclitaxel (Maschek et al., 2004), prednisolone (Ingrid, etc.) through oxidative stress and high rate glycolysis. , 2013), Sorafenib (Tesori, 2015) and 5-fluorouracil (Shin et al., 2009), injuring cancer cells. The export of ABC transporters from cancer cells to cisplatin has been shown to be dependent on glutathione (Chen and Kuo, 2010). Inhibition of glycolysis

Inhibition of glycolysis is a core strategy of therapies of the embodiments of the present disclosure. Cancer cells that are unable to use glycolysis are often starved and rely on glutamine and autophagy to supply energy. This can lead to cell necrosis. By limiting the level of blood glucose, cancer cells quickly consume their primary energy source. This will have many effects, including the aforementioned necrotic and rate limiting energy processes such as ATP-binding cassette transporters (ABC transporters). (Doyle et al., 1998)

There are currently several research reagents under the study of glucose inhibition. One such agent is dideoxyglucose (2DG), which shows efficacy in a laboratory setting and has undergone clinical trials. 2DG, which is a glucose derivative, is not phosphorylated by hexokinase and can inhibit hexokinase activity. However, 2DG fails in the clinic. One of the main failure points is 2DG-induced hyperglycemia. Despite partial hexokinase inhibition, cancer cells with elevated glucose 1 transporter (GLUT I transporters) and hexokinase levels are still able to survive in a glucose-rich environment. In addition, 2DG can cause irregular electrocardiogram (ECG) rhythms.

The core strategy for glycolysis inhibition of at least one embodiment is not to inhibit common enzymes and glucose transporters, which are overexpressed in cancer cells and require sufficient inhibitors to completely destroy and kill normal cells, but inhibit glucose utilization. The amount of cancer cells required is higher than that of normal cells to maintain their reduced state. Warburg effect of targeted chemotherapy (Warburg Effect Targeted Chemotherapy)

Waberg effect-targeted chemotherapy (WETC) uses insulin to induce hypoglycemia. Insulin does not interfere with any glycolytic enzymes. However, insulin does reduce overall blood glucose levels. Cancer tissue at normal blood glucose levels has consumed glucose, making cancer tissue more susceptible to hypoglycemia. Additional insulin-induced hypoglycemia is a rapidly reversible process that increases the safety of the therapy by providing intravenous glucose.

1 shows a schematic diagram of the difference between conventional chemotherapy and Waberg effect targeted chemotherapy for cancer stem cells in accordance with an embodiment of the present invention. As shown in Figure 1, the Wabogg effect-targeted chemotherapy is fundamentally different from conventional chemotherapy. It is characterized by: 1a) Under normal blood glucose levels, cancer cells are completely viable by using glucose to supply energy, which leads to the formation of drug resistance. ATP. Lb) High glycolysis rate leads to additional drug resistance and lc) This resistance protects cancer cell DNA against DNA damage drugs. Part 2 (right) of Figure 1 shows the Wabogg effect targeted chemotherapy, which is characterized by 2a) under hypoglycemia, cancer cells rapidly digest locally available glucose and enter a metabolic crisis, resulting in normal cancer cell function such as Lower ATP levels for ABC transporters. 2b) Lower glycolysis speed leads to drug sensitivity. 2c) The DNA of hyperglycemic cancer cells is not protected against DNA-damaging chemotherapeutic drugs, resulting in increased cancer cell death. Safety of Wabage Effect Targeted Chemotherapy - Xi'an, China

Global hospitals for treating cancer in China have used a combination of insulin-induced hypoglycemia and standard chemotherapy to treat patients, usually multiple times in a 3-week window period but at a 10% standard dose. The safety and side effects of these treatments have been evaluated.

Safety profile of insulin-induced hypoglycemia Insulin-induced 5- fluorouracil retention in cancer cells

5-fluorouracil (5-FU) is a common drug used in chemotherapy and was developed in the 1950s. 5-FU is transported into cells via a nucleotide transporter and is metabolized therefrom to several metabolites, some of which block RNA and DNA synthesis. One of the metabolites, 5-FdUMP, together with 5,10-methylenetetrahydrofolate (5,10-CH2-THF), forms a complex with thymidylate synthase (TS), which inactivates the function of TS. Inactivation of TS is used to cause DNA synthetase and repair of thymidine deficiency. This makes the synthesis phase (S phase) cells particularly sensitive to 5-FU. 5,10-CH2-THF is a downstream metabolite of folic acid whose intracellular concentration is decreased by insulin activity via a decrease in the activity of the folate export mechanism. Levofolinic acid is typically administered in conjunction with 5-FU to provide the folate precursor produced by 5,10-CH2-THF required for 5-FU and an inhibitory complex of thymidylate synthase.

A 2007 open study (Zou et al, Acta pharmacologica sinica 28.5 (2007): 721-730) showed that insulin pre-use was used prior to the addition of 5-FU compared to cells treated with 5-FU but not treated with insulin. Treatment for several hours resulted in higher cell growth inhibition and a higher percentage of apoptotic cell populations. They also showed an increase in the percentage of S-phase cells treated with insulin. They claim that the uptake of 5-FU by cells treated with insulin is enhanced, but in a way that is indirect. When the cells were treated with insulin, the 5-FU concentration in the cell culture medium was lowered, and the 5-FdUMP/5, 10-CH2-THF/TS complex was elevated. They attributed these observations to increased uptake but did not establish a link between increased folate metabolism and integration into TS complexes.

Although the pentose phosphate pathway is the major source of NAPDH in most cancer cells, folate metabolism can also produce NADPH from NADP ⁺ . Inhibition of the folate pathway, such as the use of 5-FU, and hypoglycemia-induced glucose depletion exert a combined effect by further reducing the available glutathione. Pharmacokinetics of Wabage Effect Targeted Chemotherapy

When combined with anticancer drugs and hypoglycemia, precise time settings are required. These drugs need to be at their peak in pharmacological effectiveness during the "hypoglycemia treatment window", see Figure 2. 2 shows a schematic diagram of the pharmacokinetics of a hypoglycemic glucose clamp metabolic targeted chemotherapy regimen in accordance with an embodiment of the present invention. As shown in Figure 2, depending on the pharmacological profile of the drug, the drug can be administered before, during or after induction of hypoglycemia such that its corresponding peak corresponds to the peak of the hypoglycemic treatment window. Glucose clamp as a way to induce hypoglycemia

The glucose clamp technique was first developed in 1979 and is a way to deliver insulin and glucose intravenously to precisely control blood glucose levels. This technology is used in the field of diabetes to diagnose and develop new drugs for diabetes. It has been safely used to induce hyperglycemia and hypoglycemia because it provides a well-controlled way to induce changes in blood glucose levels. Hypoglycemia has been shown to be safe at 3.0 mmol/L for up to two hours, but with altered ECG readings. (Laitinen et al., 2008) Preclinical animal trials using glucose clamps to create hypoglycemic therapeutic windows

For the purpose of diabetes research, glucose clamp technology has been well developed in animal models. (Ayala et al., 2011) We have used this technique in SCID mouse xenograft models. Figure 3 shows a schematic of this procedure. Briefly, a standard amount of cancer cells sufficient to cause tumor growth was injected subcutaneously in the back of the mouse. A few weeks later, when the tumor volume was measured at about 300-500 mm ³ , the mice were subjected to jugular vein cannulation. The mice were fasted for 5 hours before chemotherapy treatment. Depending on the pharmacokinetics of the drug, the drug is administered prior to the start of the glucose clamp or during the clamping process to correspond to the maximum effectiveness of the drug during the "hypoglycemia treatment window". A syringe pump containing insulin, glucose and washed red blood cells from the blood of the donor mouse is connected to a rotary mixer which in turn is connected to the jugular vein catheter. In order to initiate a hypoglycemic clamp, a large dose of insulin is administered to lower the initial blood glucose level, which typically takes about 30 minutes to lower blood glucose. Insulin and glucose are then administered in a stable state to maintain blood glucose levels between 30-50 mg / dL for 2 hours. In practice, blood glucose levels range from 22-51 mg / dl with an average of about 34 mg / dL (1.9 mmol / L). Figure 4 shows the results of two tests using different cancer cells and drugs. A549 cells originated from human lung cancer. The mice bearing A549 tumors were treated with pemetrexed at intervals of 2 days. Before starting the clamp, intravenous injection, 10 mg / kg, gemcitabine, intravenous injection at the beginning of hypoglycemia. Cisplatin, given intravenously at the onset of hypoglycemia, 0.5 mg / kg. HCT-116 cells are of colon cancer origin. Mice with HCT-116 tumors were given two 5-fluorouracils at intervals of 2 days. Before starting the clamp, 10 mg / kg intravenously, irinotecan, in hypoglycemia An intravenous injection of 10 mg / kg was given at the beginning. Cisplatin, given the onset of hypoglycemia, was given intravenously, 0.5 mg / kg. Wagberg effect targeted chemotherapy delivery system

The device is a machine that regulates blood glucose levels, monitors ECG rhythms, and intravenously delivers chemotherapeutic drugs via a pump system. The device is capable of regulating blood glucose levels for a longer duration than a simple one-shot method. When the device reduces blood glucose levels to a hypoglycemic state, chemotherapy is delivered to the patient via a number of pumps positioned within the device. The chemotherapeutic drug is contained in a special cartridge designed to be only suitable for positioning in a chemotherapy pump within the device, while insulin and glucose each have their own dedicated cartridge, which makes incorrect loading of the machine impossible (ie insulin cartridge) Pumps that will not be physically suitable for glucose or chemotherapy drugs, and vice versa). Because the system is a direct pump supply, the device also includes a magnetic mixer for diluting insulin, glucose and chemotherapeutic drugs to saline (saline is also delivered by a pump in a dedicated cartridge).

The device controls blood glucose levels and delivers chemotherapeutic drugs while also having many safety features. The main safety consideration for hypoglycemia is abnormal heart rhythm. Although prolonged (about 2 hours) hypoglycemia using glucose clamps is generally safe in healthy individuals, we are treating cancer patients with multiple secondary lesions and require additional care. An integrated ECG monitor is incorporated that is capable of triggering a glucose pump to increase blood glucose levels and/or reduce or stop insulin administration in the event of an irregular heartbeat. An externally manually controlled glucose syringe is also available, which can be operated by a medical professional. For accurate drug delivery, the device includes a bar code reader (or RFID chip or other authentication mechanism) that correctly identifies the chemotherapeutic drug cartridge, so the medical staff can correctly load the drug to be accepted by the patient into the machine and illuminate the correct pump for the corresponding drug Light-emitting diode above the cavity. In addition, the device can use the authentication mechanism to confirm that the box has not been reused or spoofed, in particular by connecting to a central database via a wired or wireless connection and verifying that the authenticated box is valid and/or has not been used before.

The device has integrated software that receives feedback from continuous blood glucose monitors and ECG monitors and interprets these feedbacks for display and pumping action, such as adding glucose due to blood glucose levels falling below the target range. The software package can be pre-programmed to deliver precise drug doses by controlling pump piston motion and by barcode readers to ensure that the correct chemotherapeutic drug is loaded according to a pre-programmed treatment protocol. The device can accept protocols based on cancer type and other variable suggestion protocols and/or via wired or wireless connections. If the accepted plan is different from the recommended one, the device can issue a warning that can be rejected by the medical staff. Chemotherapy under hypoglycemia

The device uses insulin to lower blood glucose levels and subsequently to reduce the level of chemotherapeutic drugs. These treatments are repeated frequently (several times a week) to achieve a clinical response. Long-term hypoglycemia during chemotherapy treatment, about 2 hours, is necessary because the half-life activity of many chemotherapeutic drugs is within this range. The standard treatment is to first reduce the blood glucose concentration by half the normal level by intravenous injection of insulin. Subsequently, while hypoglycemia is induced, the chemotherapeutic drug is delivered over a period of time ranging from a few minutes up to several hours. Hypoglycemia is maintained during treatment by injecting additional insulin or glucose to regulate blood glucose levels. The ECG rhythm is monitored during this time by injecting glucose at the onset of a bad cardiac event to pull blood glucose levels back to normal to prevent any adverse cardiac events. Mechanical characteristics of the WETC delivery system: • A continuous blood glucose monitoring system capable of delivering (potentially up to minutes or real time) blood glucose levels on a regular basis. An insulin/glucose pump adjustment system capable of maintaining a predetermined blood glucose level. • Multiple pump systems that are capable of delivering not only insulin and glucose but also several chemotherapeutic drugs. • An internal magnetic mixer that can mix insulin, glucose and/or chemotherapeutic drugs with saline to deliver a constant fluid flow to the patient even when the protocol requires a slower drug flow rate. The mixer is capable of diluting the chemotherapeutic drug to saline, which would otherwise be higher than the desired concentration for intravenous delivery. • Use wired or wireless technology to connect blood glucose and/or ECG monitors. • Includes USB, Firewire, Wired Ethernet, Wireless Ethernet, Serial Port and other computer interfaces to update firmware and download and upload patient data and verify the box. Safety features of the WETC delivery system: • An ECG monitoring system that is capable of responding to any adverse cardiac events and alerting the patient to normal blood glucose levels. • A secondary calibration blood glucose monitor is integrated into the machine that tests fresh patient blood extracted from the scalpel, vein or port to ensure that the continuous blood glucose monitor reads blood glucose levels correctly. • An external glucose delivery syringe for manual glucose delivery. • Barcode readers and LED light systems to ensure that the correct drug is placed in the correct pump slot. · A unique adapter for the correct pump cavity for insulin, glucose and drug pumps only. · A large display of current blood glucose levels and ECG status can be easily read out even across the room. • The pressure sensor will show a blocked port or intravenous line and turn off the machine pump to prevent excessive pressure on the line and veins. • Place an anti-backflow valve according to the main input line pipe and suppress backflow from the patient to the machine. • The coaxial gas detector prevents bubble embolism by detecting gas and moving the gas from the main line to the waste container. • System heater control condenses, which can occur when a cold insulin, glucose or drug cartridge (usually refrigerated) is placed in the device before returning to room temperature. The software features of the WETC delivery system software can be programmed using patient information and its treatment plan. • The software is capable of storing patient information and treatments in local and remote databases. • The pumping solution interprets the bar code label on the drug box and illuminates the LED light, so the medical staff correctly loads the different pumps using the correct drug box. • Software controls the display panel and speakers for video and audio output. • Software reads monitoring feedback from blood glucose and ECG monitors and interprets these feedbacks to pump insulin or glucose to maintain proper blood glucose levels. • The software is capable of handling adverse events such as irregular heartbeats and taking appropriate actions such as glucose injections and warning medical staff. • The software is capable of controlling the pump to deliver a precise dose of chemotherapeutic drug over a variable period of time by controlling the flow rate of the pump and the total delivery volume. • The software controls the saline pump flow rate to provide both the drug and saline to the mixer for proper drug dilution. • The software has a solution for flushing/cleaning the system and removing air from the pipeline. • A human-machine interface with buttons and touch screen display technology. • Use passwords, swipe cards and/or fingerprint authentication, so only medical staff can use machine functions.

FIG. 5 is a diagram of a system 300 for chemotherapy delivery, in accordance with an embodiment of the present invention. System 300 includes a plurality of cartridges 310, 312, 314, 316, and 318 for insulin, glucose, chemotherapeutic drugs, and/or other drugs and/or saline, a plurality of pumps (not shown in FIG. 5) configured to receive a plurality of cartridges 310, 312, 314, 316 And 318, blood glucose sensor 320, mixer 350, may include a display 330 of the GUI, an ECG monitor system 340 having an ECG lead, a processor (not shown in Figure 5), communicatively coupled to Figure 6 and Figure Other components discussed in further detail in 7.

FIG. 6 is a diagram of a system 400 for chemotherapy delivery in accordance with an embodiment of the present invention. Referring to Figure 6, a system 400 for chemotherapy delivery includes a plurality of slots 410, wherein each of the plurality of slots 410 is configured to receive a corresponding one of the plurality of cartridges 420; a plurality of pumps 430, wherein the plurality of pumps 430 Each of the plurality of cartridges is configured to be coupled to a corresponding one of the plurality of cartridges, and the plurality of pumps 430 are configured to pump at least one drug contained in at least one of the plurality of cartridges 420 in accordance with a treatment protocol. At least one of the drugs includes insulin, glucose, and at least one chemotherapeutic drug, and the plurality of cartridges 420 are configured to contain insulin, glucose, and at least one chemotherapeutic drug, respectively. System 400 also includes a blood glucose sensor 440 communicatively coupled to a plurality of pumps 430 and configured to measure a blood glucose level of the patient; a processor 450 coupled to the plurality of pumps and the blood glucose sensor, and configured to be based on the measured patient The blood glucose level adjusts the delivery characteristics of the at least one drug; and wherein the plurality of pumps 430 are further configured by the processor 450 to adjust the pumping of the at least one drug based on the adjusted delivery characteristics.

FIG. 7 is a block diagram of a system 500 for chemotherapy delivery in accordance with another embodiment of the present invention. System 500 includes a plurality of cartridges 420, a plurality of pumps 430, a plurality of cartridges 520 of blood glucose sensors 440, a plurality of pumps 530, and a blood glucose sensor 540, respectively, similar to that shown in FIG. Optionally, one of the plurality of cartridges 420 includes saline, and the system 400 further includes a mixer 555 coupled to the plurality of cartridges 520 and the processor 550 and configured to be diluted with physiological saline according to the adjusted delivery characteristics Insulin, glucose, and at least one chemotherapeutic drug are used to dilute at least one drug, in admixture, wherein the mixer 550 is further configured to deliver the diluted drug to the patient.

Optionally, system 500 also includes an ECG monitoring system 560 communicatively coupled to processor 550 that is configured to monitor the heart rhythm of the patient. The processor 560 is further configured to adjust delivery characteristics of the at least one drug based on the measured blood glucose level and heart rate of the patient; wherein the plurality of pumps 530 are further configured by the processor 550 to adjust pumping of the at least one drug based on the adjusted delivery characteristics.

Optionally, the ECG monitoring system 560 is further configured to indicate to the processor 550 that a bad cardiac event is detected for the patient; and the processor 550 is further configured to instruct the plurality of pumps 530 to change the amount of insulin and/or glucose pumped by Return the patient to normal blood sugar levels.

Optionally, the processor 550 is further communicably coupled to the server 590 and configured to download patient data from the server 590; wherein the plurality of pumps 530 are further configured by the processor 550 to adjust pumping of the at least one medication based on the patient data.

Optionally, wherein each of the plurality of slots 510 includes a chamber sized to receive a corresponding one of the plurality of cartridges.

Optionally, system 500 further includes a display 565 communicatively coupled to ECG monitoring system 560 and blood glucose sensor 540 and configured to display current blood glucose levels and ECG based on data received from ECG monitoring system 560 and blood glucose sensor 540. status.

Optionally, system 500 further includes a pressure sensor 570 coupled to a plurality of pumps 530 configured to stop pumping of the plurality of pumps 530 if the pressure sensor 570 detects that the patient's blood pressure is above a threshold.

Optionally, system 500 further includes a waste container 575, an air detector 580 coupled to the waste container 575 and an output line of the plurality of pumps 530, and configured to discharge air from the output line into the waste container 575 .

Optionally, system 500 further includes a heater 585 disposed adjacent the plurality of cartridges, the heater 585 configured to remove at least one of the plurality of cartridges 520 by heating at least one of the plurality of cartridges 520 to room temperature Condensate.

Optionally, the delivery properties of the at least one drug include drug delivery flux, drug delivery amount, treatment time, remaining treatment amount, drug being administered, remaining drug administration, drug administered, duration of drug, sequence of drug to be delivered .

FIG. 8 is a block diagram showing processing system 600. The processing system 600 includes a scenario logic 605, a box logic 610, display logic 615 (which may include GUI logic), pump logic 620, glucose logic 625, ECG logic 630, mixer logic 635, and communication logic 640.

During operation of the device, the scenario logic 605 receives the patient's plan, which is received via manual input (via an input device such as a GUI) or via communication logic 640, wired or wireless. In one embodiment, the scenario logic 605 can verify that the protocol meets the type and/or stage of the cancer. For example, breast cancer chemotherapy drugs should be given to breast cancer patients rather than lung cancer patients. This verification can be accomplished by examining the database within the device and/or checking the external database of the connection communication logic 640. In another embodiment, the user can enter the type and/or stage of the cancer and receive the recommended protocol, which the user can then accept. Once the protocol is received, it is displayed by display logic 615 on the display, and in one embodiment the user can accept the solution (eg, confirm that it is correct and positively responding to the correct person to prevent incorrect administration to the patient) Drug).

Once the plan data is received/received, the box logic 610 can display which box entered which pump, which is adjacent to the pump and/or text and/or color on the display (eg, the box and pump can be color coded) Display this information. For example, the display can indicate that the insulin cartridge is inserted into the leftmost pump and the display on the pump can record insulin and/or be color coded. Note that at least some of the pumps may have a static label of the type of display cartridge, provided that the pump always uses the same content (eg, the leftmost pump is available for insulin, so no active display is required).

In one embodiment, the above operations can be performed automatically without any human interaction. For example, when displaying a pump indicating insertion of the insulin cartridge into the leftmost side, the robotic arm is programmed to insert the insulin cartridge into the leftmost pump in accordance with a predetermined instruction and a statement on the display.

Once the cartridge is inserted, the cartridge logic 610 further reads the authentication mechanism on each inserted cartridge to verify that the correct cartridge is inserted into the respective pump. Alternatively or additionally, the pump can be configured and/or shaped to accept only a particular cartridge based on the content. The mechanism can be barcodes, RFID, magnetic strips, holograms, and the like. In one embodiment, the communication logic 640 is coupled and the box logic 610 can contact the database to verify the authenticity of the cartridge and/or verify that the cartridge is not being reused, re-using the medication that can cause contamination problems and/or being counterfeited. For example, if the box ID is not in the database, the box is very likely to be counterfeit, which means a security issue for the patient. If the box ID is in the database but appears to have been previously used, the box may be counterfeit or use potentially counterfeit, contaminated and/or unauthorized drug refills. If the verification fails, display logic 615 can present an alert for the relevant information and prevent the box contents from being given. If the verification passes, the database self-updates to show that the box has been used.

In one embodiment, the box logic 610 checks the expiration date of the box and does not activate the device if the box has expired.

In one embodiment, the information identifying the information, such as the box logic 610 to identify the authenticity of the cartridge and/or identifying whether the cartridge is reused, includes checksums and other designs to verify authenticity. This is useful when you are unable to connect to the database.

Display logic 615 displays messages and other information on the display. It receives data from other components of the device for display, either directly or via a processing system. The display logic 615 can display electrocardiogram data, blood glucose data, dosing instructions, process information (eg, stage information, hypoglycemia time, treatment time, remaining treatment, blood glucose levels; medication being administered, remaining to be administered) Drugs, drugs given, etc.), patient data, protocol data, etc.

After the scenario is received and the box logic 610 verifies the cartridge, the pump logic 620 begins to give the cartridge contents according to the received scheme. During administration, protocol logic 605 updates the status of administration on the display. As mentioned previously, administration includes administration of insulin to lower blood glucose levels and subsequent administration of the drug. Note that pump logic 620 can pump some or all of the contents of the cartridge into the mixer prior to administration to the patient. For example, the chemotherapeutic drug and saline can be pumped into the mixer first, followed by administration of the mixture to the patient. Glucose logic 625 receives blood glucose levels from a blood glucose monitor. Display logic 615 displays blood glucose levels on the display. If glucose logic 625 determines that the blood glucose level is too low (eg, 2.2 mmol / L), it causes pump logic 520 to administer glucose to the patient such that blood glucose levels are increased. Similarly, ECG logic 630 receives data from the ECG monitor and, if the data is abnormal, informs glucose logic 625 that it will instead administer glucose as described above. It is also noted that in both cases, the glucose logic 625 or ECG logic 630 can cause the device to issue a warning (audio, video, and/or text, etc.). In this case, the user can also manually give glucose. In addition, upon completion of the protocol, glucose logic 625 will cause pump logic 620 to administer glucose to raise blood glucose levels to normal levels (eg, greater than 5.4 mmol/L).

Mixer logic 635 controls the mixer to mix the contents of the cartridge according to the protocol. The mixer then gives the mixture to the patient.

Communication logic 640 communicates via a wired or wireless connection to receive a patient protocol or communicate with one or more databases as described above.

9 is a high level schematic diagram showing an example architecture 700 of the architecture 300 of the system of FIG. Architecture 700 includes a memory 720 coupled to interconnect 760 and one or more processors 710. The interconnect 760 shown in Figure 9 is an abstraction concept, representing any one or more separate physical buses, point-to-point connections, or both, connected by appropriate bridges, adapters, or controllers. Thus, interconnect 760 can include, for example, a system bus, a form of external device interconnect (PCI) bus, a hypertransport or industry standard architecture (ISA) bus, a small computer system interface (SCSI) bus, a universal serial bus (USB), IIC ( The I2C) bus, or the Institute of Electrical and Electronics Engineers (IEEE) standard 1394 bus, also becomes a "firewire", and/or any other suitable form of physical connection.

Processor 710 is the central processing unit (CPU) of architecture 700 and thus controls the overall operation of architecture 700. In some embodiments, processor 710 implements this functionality by executing software or firmware stored in memory 720, which will thus store the logic of FIG. For example, scheme logic 605, box logic 610, display logic 615, and the like. Processor 710 can be or can include one or more programmable general purpose or special purpose microprocessors, digital signal processors (DSPs), programmable controllers, application specific integrated circuits (ASICs), programmable logic devices (PLDs), and the like. , or a combination of such devices.

Memory 720 is or includes main memory of architecture 700. Memory 720 represents any form of random access memory (RAM), read only memory (ROM), flash memory, etc., or a combination of such devices. Software or firmware code for implementing at least some embodiments of the present invention may also be included in addition to others.

Also connected to processor 710 via interconnect 760 is a communication interface 740 such as, but not limited to, network adapter 740, one or more output devices 730 (eg, the display of FIG. 5), one or more input devices 750 (eg, 5 monitors, provided the display is touch sensitive). Network adapter 740 provides architecture 700 with the ability to communicate with remote devices over internetwork 730 and can be, for example, an Ethernet adapter or a Fibre Channel adapter. Input device 750 can include a touch screen, a keyboard and/or a mouse, and the like. Output device 730 can include a screen and/or a speaker or the like.

The techniques introduced by the present invention may be implemented by programmable circuitry programmed/configured in software and/or firmware, or entirely by dedicated circuitry, or by a combination of such forms. Such dedicated circuits, if any, may be in the form of, for example, one or more application specific integrated circuits (ASICs), programmable logic devices (PLDs), field programmable gate arrays (FPGAs), and the like.

Software or firmware for implementing the techniques introduced by the present invention may be stored on a machine readable storage medium and executed by one or more general purpose or special purpose programmable microprocessors. As used herein, "machine-readable medium" includes any mechanism that can store information in a machine-accessible form (the machine can be, for example, a computer, a network device, a cell phone, a personal digital assistant (PDA), a manufacturing tool, having one or more Any device of the processor, etc.). For example, machine-accessible media include recordable/non-recordable media (eg, read only memory (ROM); random access memory (RAM); magnetic disk storage media; optical storage media; flash memory, etc.) and the like.

The term "logic" is used herein to mean: a) dedicated hard-wired circuitry, such as one or more application specific integrated circuits (ASICs), programmable logic devices (PLDs), field programmable gate array FPGAs, or other similar devices; a programmable circuit programmed with software and/or firmware, such as one or more programmed general purpose processors, digital signal processors (DSPs) and/or microcontrollers, or other similar devices; or c) in a) and The combination of the forms mentioned in b).

Figure 10 is a flow chart showing how the device operates. In one embodiment, the logic of Figure 8 can implement the method. First, the scheme data is received in block 805. The protocol data includes drugs (eg, cancer therapy, insulin) and other agents (eg, saline, glucose) for administration according to sequence and duration and/or in combination. An example of a solution can be found in the accompanying WO 2012/075679 Al. Then at block 810, the scheme can optionally be verified as described above. Then at block 815, the cartridge slots for each drug and reagent are displayed, and which slot/pump is used for which cartridge. Subsequently, at block 820, the authenticity, reuse, and/or expiration of the cartridge is verified. After verification, the method can include notifying the database to update the used box records to prevent future refills and reuse.

Subsequently, at block 825, insulin is administered to lower blood glucose levels, which can be monitored throughout the method. Insulin is administered continuously until low blood glucose levels are achieved (eg, to 2.8 - 4.5 mmol/L or 2.2 mmol/L). When method 800 determines that blood glucose levels are sufficient, method 800 proceeds to blocks 835 and 840, followed by mixing saline and a drug (eg, a chemotherapeutic agent) and administering the mixture. If method 800 determines that the blood glucose level is insufficient, then method 800 returns to block 825 to continue administering insulin. Note that insulin can be administered continuously to maintain the target blood glucose level.

During the administration, blood glucose levels are constantly monitored, and method 800 determines at block 845 whether the blood glucose level is low. If the blood glucose level is below a predetermined level (e.g., 2.2 mmol/L), glucose is administered in block 855 to raise blood glucose levels. Moreover, during the method 800, if the ECG is continuously monitored and if an abnormality is displayed at block 850, glucose can be administered at block 855. Note that if the blood glucose level drops too low and/or the ECG is abnormal, the method can include alerting with sound and/or vision (eg, on a display). The method is then terminated. Note that many parts of the method can be performed almost simultaneously and/or in an order different from the order presented. In addition, some parts may be omitted.

11 is a flow chart showing an example of a chemotherapy delivery method 900 in accordance with an embodiment of the present invention.

The method 900 includes receiving, in block 905, a corresponding one of the plurality of cartridges by each of the plurality of slots; in block 910, each of the plurality of pumps connected to a corresponding one of the plurality of cartridges, according to the treatment The solution pumps at least one drug contained in at least one of the plurality of cartridges. The at least one drug includes insulin, glucose, and at least one chemotherapeutic drug, and the plurality of cartridges are configured to contain insulin, glucose, and at least one chemotherapeutic drug, respectively. The method 900 also includes, at block 915, measuring a blood glucose level of the patient by a blood glucose sensor communicatively coupled to the plurality of pumps; at block 920, by the processor coupled to the plurality of pumps and the blood glucose sensor, based on the measured blood glucose level of the patient To adjust the delivery characteristics of the at least one drug; and at block 925, pumping of the at least one drug is adjusted by the plurality of pumps based on the adjusted delivery characteristics.

Optionally, the method 900 further includes (not shown in FIG. 11) diluting the insulin, glucose, and the at least one chemotherapeutic drug to dilute the at least one drug according to the adjusted delivery characteristics by a mixer coupled to the plurality of cartridges and the processor, and The mixer delivers the diluted drug to the patient.

Optionally, the method 900 further includes (not shown in FIG. 11) monitoring the cardiac rhythm of the patient by an ECG monitoring system communicatively coupled to the processor; adjusting at least one of the measured blood glucose levels and heart rhythms by the processor The delivery characteristics of the drug; and the pumping of the at least one drug by the plurality of pumps in accordance with the adjusted delivery characteristics.

Optionally, the method 900 further includes (not shown in FIG. 11) indicating to the processor by the ECG monitoring system that a bad cardiac event is detected for the patient; and instructing the plurality of pumps by the processor to change the pumping of insulin and/or glucose The amount is used to return the patient to normal blood sugar levels.

Optionally, method 900 further includes (not shown in FIG. 11) downloading patient data from a server by a processor communicably coupled to the server; adjusting pumping of the at least one medication based on the patient data by the plurality of pumps.

Optionally, each of the plurality of pumps includes a chamber sized to receive the corresponding one of the plurality of cartridges.

Optionally, the method 900 further includes (not shown in FIG. 11) displaying the current blood glucose level based on data received from the ECG monitoring system and the blood glucose sensor by a display communicatively coupled to the ECG monitoring system and the blood glucose sensor And ECG status.

Optionally, the method 900 further includes (not shown in FIG. 11) stopping the pumping of the plurality of pumps by a pressure sensor coupled to the plurality of pumps if the pressure sensor detects that the patient's blood pressure is above a threshold.

Optionally, the method 900 further includes (not shown in Figure 11) discharging air from the output line into the waste container by an air detector connected to the waste container and the output lines of the plurality of pumps.

Optionally, the method 900 further includes (not shown in FIG. 11) removing at least one of the plurality of cartridges by heating at least one of the plurality of cartridges to room temperature by a heater placed in the vicinity of the plurality of cartridges Condensate.

Optionally, the delivery properties of the at least one drug include drug delivery flux, drug delivery amount, treatment time, remaining treatment amount, drug being administered, remaining drug administration, drug administered, duration of drug, sequence of drug to be delivered .

In accordance with another embodiment of the present invention, a computer readable storage medium, the stored instructions, when executed by a processor, cause a computer to perform operations comprising: controlling each of a plurality of pumps connected to a respective one of the plurality of cartridges Pumping at least one drug contained in at least one of the plurality of cartridges according to a treatment protocol, wherein the at least one drug comprises insulin, glucose, and at least one chemotherapeutic drug, and the plurality of cartridges are configured to respectively contain insulin, glucose, and at least one a chemotherapeutic drug; a blood glucose sensor communicatively coupled to the plurality of pumps to measure a blood glucose level of the patient; a delivery characteristic of the at least one drug adjusted according to the measured blood glucose level of the patient; and controlling the plurality of pumps to be adjusted according to the adjusted delivery characteristics Pumping of at least one drug.

Optionally, wherein one of the plurality of cartridges comprises saline, the operation further comprising controlling a mixer coupled to the plurality of cartridges and the processor to dilute the insulin, glucose, and at least one chemotherapeutic drug with saline to dilute the at least according to the adjusted delivery characteristics A medicament, and controlling the mixer to deliver the diluted medicament to a patient.

Optionally, the operations further comprise reading the heart rhythm of the patient by an ECG monitoring system communicatively coupled to the processor; adjusting delivery characteristics of the at least one drug based on the measured blood glucose level and heart rate of the patient; and controlling the plurality of pumps according to the measurement The blood sugar level and the patient's heart rhythm adjust the pumping of at least one drug to maintain a proper blood sugar level.

Optionally, the operating further comprises monitoring the detection of a bad cardiac event by the ECG monitoring system for the patient; and instructing the plurality of pumps to return the patient to a normal blood glucose level by varying the amount of pumped insulin and/or glucose.

Optionally, the operating further comprises downloading patient data from the server; controlling the plurality of pumps to adjust pumping of the at least one medication based on the patient data; storing the adjusted delivery characteristics in the data store.

Optionally, the operating further comprises controlling the display communicatively coupled to the ECG monitoring system and the blood glucose sensor to display the current blood glucose level and the ECG status based on data received from the ECG monitoring system and the blood glucose sensor.

Optionally, the operations further comprise controlling audio communicatively coupled to the ECG monitoring system and the blood glucose sensor to output an audio signal indicative of the current blood glucose level and the ECG status based on the data received from the ECG monitoring system and the blood glucose sensor.

References to "an embodiment", "an embodiment" or the like in this specification means that the particular features, functions, structures or characteristics described are included in at least one embodiment of the invention. The appearances of such phrases in the specification are not necessarily referring to the same embodiment. On the other hand, such references are not necessarily mutually exclusive.

It is noted that any and all of the above-described embodiments may be combined with each other unless otherwise stated above or any such embodiments may be mutually exclusive in function and/or structure. reference document

All of the references listed below, as well as all references cited in the above specification, are hereby incorporated by reference in their entirety in their entirety in their entirety. Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, Kinoshita T, Saito N, Ochiai A, Tomita M, Esumi H. Quantitative metabolome of colon and gastric cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer research. 2009 Jun 1;69(11):4918-25. Vaughn AE, Deshmukh M. Glucose metabolism Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nature cell biology. 2008 Dec 1;10(12):1477-83. Patra KC, Hay N. The pentose phosphate pathway and cancer. Trends in biochemical sciences. 2014 Aug 31;39(8):347-54. Cao X, Fang L, Gibbs S, Huang Y , Dai Z, Wen P, Zheng X, Sadee W, Sun D. Glucose uptake inhibitors make cancer cells sensitive to daunorubicin and overcome resistance during hypoxia (Glucose Uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia). Cancer chemotherapy and pharmacology. 2007 Mar 1;59(4):495-505. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF , De Young LR, Lampidis TJ. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in humans in human osteosarcoma and non-small cell lung cancer (2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human Cancer research. 2004 Jan 1;64(1):31-4. Ariës IM, Hansen BR, Koch T, van den Dungen R, Evans WE, Pieters R, den Boer The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistance. ML. MCL1 and glycolysis on the survival and prednisolone resistance of pediatric acute lymphoblastic leukemia cells. haematologica. 2013 Oct 18: Haematol-2013. Tesori V, Piscaglia AC, Samengo D, Barba M, Bernardini C, Scatena R, Pontoglio A, Castellini L, Spelb Rink JN, Maulucci G, Puglisi MA. The multi-kinase inhibitor sorafenib enhances glycolysis and synergizes with glycolysis to kill cancer cells (The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell Killing). Scientific reports. 2015 Mar 17;5:9149. Shin YK, Yoo BC, Hong YS, Chang HJ, Jung KH, Jeong SY, Park JG. Among proteins secreted by 5-fluorouracil-resistant human colon cancer cells Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance. Electrophoresis. 2009 Jun 1;30(12):2182-92. Helen HW C, Macus Tien K. Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy. Metal-based drugs. 2010 Sep 14;2010. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. Multidrug resistance transporter from human MCF-7 breast cancer cells (A multidrug resistance transporter from human MCF-7 breast cancer cells). Proceedings of the National Academy of Sciences. 1998 Dec 22;95(26):15665-70. Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, DiPaola RS, Stein MN, Lima CM, Schlosselman JJ, Tolba K, Langmuir VK, Kroll S. 2-Deoxy-D-glucose alone or in combination with docetaxel in the treatment of advanced solid tumors in a phase I dose escalation trial (A phase I dose-escalation trial of 2-deoxy-D -Zum K, XIE H. Pretreatment with insulin to enhance human esophageal cancer and colon cancer Pretreatment with insulin enhances anticancer functions of 5-fluorou-racil in human esophageal and colonic cancer cells. Acta pharmacologica sinica. 2007 May 1;28(5):721-30. Laitinen T , Lyyra-Laitinen T, Huopio H, Vauhkonen I, Halonen T, Hartikainen J, Niskanen L, Laakso M. Electrocardiogram changes in hyperinsulinemia, hypoglycemia, healthy people (Electrocardiographic alterati Ons during Noninvasive Electrocardiology. 2008 Apr 1;13(2):97-105. Ayala JE, Bracy DP, Malabanan C, James FD, Ansari T, Fueger PT, McGuinness OP, Wasserman DH Hyperinsulinemic-euglycemic clamps in consciousness, unrestrained mice. Journal of visualized experiments: JoVE. 2011 (57).

300‧‧‧System for chemotherapy delivery
310, 312, 314, 316 and 318‧ ‧ multiple boxes
320‧‧‧ Blood glucose sensor
330‧‧‧ display
340‧‧‧ECG monitor system
350‧‧‧ Mixer
410‧‧‧ slots
420‧‧‧ box
430‧‧‧ pump
440‧‧‧ Blood glucose sensor
450‧‧‧Processor
510‧‧‧ slot
520‧‧‧ box
530‧‧‧ pump
540‧‧‧ Blood glucose sensor
550‧‧‧ processor
560‧‧‧ECG monitoring system
565‧‧‧ display
570‧‧‧ Pressure sensor
580‧‧ Air detector
585‧‧‧heater
590‧‧‧ server
600‧‧‧Processing system
605‧‧‧Program Logic
610‧‧‧ box logic
615‧‧‧ Display logic
620‧‧‧ pump logic
625‧‧‧Glucose Logic
630‧‧‧ECG Logic
635‧‧‧ Mixer Logic
640‧‧‧Communication logic
700‧‧‧Architecture
710‧‧‧ processor
720‧‧‧ memory
730‧‧‧output device
740‧‧‧Network adapter
750‧‧‧ input device

1 shows a schematic diagram of the difference between conventional chemotherapy and Waberg effect targeted chemotherapy for cancer stem cells in accordance with an embodiment of the present invention. 2 shows a schematic diagram of the pharmacokinetics of a hypoglycemic glucose clamp metabolic targeted chemotherapy regimen in accordance with an embodiment of the present invention. Figure 3 shows a diagram of a glucose clamp procedure performed by flanking tumor mice. Figure 4 is the result from two different glucose clamp plus chemotherapy procedures performed on mice of different tumor types derived from different human cancer cell lines. Figure 5 is a diagram of a system for chemotherapy delivery in accordance with an embodiment of the present invention. 6 is a diagram of a system for chemotherapy delivery in accordance with an embodiment of the present invention. 7 is a block diagram of a system for chemotherapy delivery in accordance with another embodiment of the present invention. FIG. 8 is a block diagram showing processing system 600. 9 is a high level expanded view showing an example of an architecture of an apparatus for chemotherapy delivery according to an embodiment of the present invention. 10 is a flow chart of an example of a chemotherapy delivery method in accordance with an embodiment of the present invention. 11 is a flow chart of an example of a chemotherapy delivery method in accordance with another embodiment of the present invention.

Claims (41)

A system for chemotherapy delivery, comprising: a plurality of troughs, wherein each of the plurality of troughs is configured to receive a corresponding one of a plurality of cartridges; a plurality of pumps, wherein each of the plurality of pumps One configured to connect to a corresponding one of the plurality of cartridges, and the plurality of pumps are configured to pump at least one drug contained in at least one of the plurality of cartridges according to a treatment regimen, wherein The at least one drug comprises insulin, glucose and at least one chemotherapeutic drug, and the plurality of cartridges are configured to contain insulin, glucose and at least one chemotherapeutic drug, respectively; a blood glucose sensor communicatively coupled to the plurality of pumps, and Configuring to measure blood glucose levels of the patient; a processor coupled to the plurality of pumps and the blood glucose sensor, and configured to adjust delivery of the at least one drug based on the measured blood glucose level of the patient And wherein the plurality of pumps are further configured by the processor to adjust pumping of the at least one drug based on the adjusted delivery characteristics. The system of claim 1, wherein one of the plurality of cartridges comprises brine, and the system further comprises: a mixer coupled to the plurality of cartridges and the processor, the mixer being Configuring to dilute the insulin with the saline, the glucose and the at least one chemotherapeutic drug to dilute the at least one drug by adjusting the delivery characteristics, A system of claim 1, further comprising an ECG monitoring system communicatively coupled to the processor, configured to monitor a cardiac rhythm of the patient; wherein the processor is further configured to measure a patient Blood glucose levels and heart rhythms to adjust delivery characteristics of the at least one drug; wherein the plurality of pumps are further configured by the processor to adjust pumping of the at least one drug based on the adjusted delivery characteristics. The system of claim 3, wherein the ECG monitoring system is further configured to indicate to the processor that a bad cardiac event is detected for the patient; and the processor is further configured to indicate the plurality The pumps return the patient to normal blood glucose levels by varying the amount of insulin and/or glucose pumped. The system of claim 1, wherein the processor is further communicably coupled to a server and configured to download patient data from the server; wherein the plurality of pumps are further configured by the processor to The patient data is used to adjust pumping of the at least one drug. The system of claim 1, wherein each of the plurality of slots comprises a chamber sized to receive the corresponding one of the plurality of cartridges. A system of claim 3, further comprising: a display communicatively coupled to the ECG monitoring system and the blood glucose sensor, and configured to display based on data received from the ECG monitoring system and the blood glucose sensor Current blood glucose levels and ECG status. The system of claim 1, further comprising: a pressure sensor coupled to the plurality of pumps, configured to stop the plurality of pumps if the pressure sensor detects that the patient's blood pressure is above a threshold Pumping. The system of claim 1, further comprising: a waste container; an air detector connected to the waste container and an output line of the plurality of pumps, and configured to extract air from the The output line is discharged into the waste container. A system as claimed in claim 1, further comprising a heater disposed adjacent to the plurality of cartridges, the heater being configured to be removed by heating the at least one of the plurality of cartridges to room temperature Condensate in the at least one of the plurality of cartridges. The system of claim 1, wherein the at least one drug delivery property comprises a drug delivery flow, a drug delivery amount, a treatment time, a remaining treatment amount, a drug being administered, a remaining drug, a drug administered, The duration of the drug, the order of the drugs to be delivered, wherein the treatment regimen comprises at least one of the administered drug and the agent, the duration of administration, and combinations thereof. The system of claim 1, wherein the processor is further configured to control blood glucose levels for a period of time by using a glucose clamp technique. A system of claim 12, wherein the processor is further configured to control blood glucose levels to cause hypoglycemia for up to two hours by using the glucose clamp technique. The system of claim 1, wherein the plurality of pumps are further configured by the processor to adjust pumping the at least according to the adjusted delivery characteristics prior to the hypoglycemic treatment window induced by the hypoglycemic glucose clamp a drug. The system of claim 1, wherein the plurality of pumps are further configured by the processor to adjust pumping the at least according to adjusted delivery characteristics during a hypoglycemic treatment window induced by hypoglycemic glucose clamps a drug. A method for chemotherapy delivery, comprising: receiving a corresponding one of a plurality of cartridges by each of a plurality of slots; a plurality of pumps each connected to a corresponding one of the plurality of cartridges, according to the treatment The solution pumps at least one drug contained in at least one of the plurality of cartridges, wherein the at least one drug comprises insulin, glucose, and at least one chemotherapeutic drug, and the plurality of cartridges are configured to contain insulin, glucose, respectively And at least one chemotherapeutic drug; a blood glucose sensor communicatively coupled to the plurality of pumps to measure blood glucose levels of the patient; by a processor coupled to the plurality of pumps and the blood glucose sensor, based on the measured The patient's blood glucose level is adjusted to adjust delivery characteristics of the at least one drug; and pumping of the at least one drug is adjusted by the plurality of pumps in accordance with the adjusted delivery characteristics. The method of claim 16, further comprising diluting the insulin with the brine, the glucose and the at least one by a mixer connected to the plurality of cartridges and the processor according to adjusted delivery characteristics A chemotherapeutic drug is used to dilute the at least one drug, and the diluted drug is delivered to the patient by the mixer. The method of claim 16, further comprising monitoring, by the ECG monitoring system communicatively coupled to the processor, a cardiac rhythm of the patient; adjusting, by the processor, the measured blood glucose level and heart rate of the patient The delivery characteristics of the at least one drug; and the pumping of the at least one drug by the plurality of pumps in accordance with the adjusted delivery characteristics. The method of claim 18, further comprising indicating, by the ECG monitoring system, the processor to detect a bad cardiac event for the patient; and instructing, by the processor, the plurality of pumps to change pumping The amount of insulin and/or glucose is used to return the patient to normal blood glucose levels. The method of claim 18, wherein the processor is communicably connected to the server to download patient data from the server; the plurality of pumps adjust the at least one drug based on the patient data Pumping. The method of claim 16, wherein each of the plurality of pumps includes a chamber sized to receive the corresponding one of the plurality of cartridges. The method of claim 18, further comprising: displaying, by the display communicatively coupled to the ECG monitoring system and the blood glucose sensor, data based on data received from the ECG monitoring system and the blood glucose sensor Blood sugar levels and ECG status. The method of claim 16, further comprising: if the pressure sensor detects that the blood pressure of the patient is above a threshold, stopping pumping of the plurality of pumps by the pressure sensor connected to the plurality of pumps . The method of claim 16, further comprising: discharging air from the output line into the waste container by an air detector connected to the waste container and an output line of the plurality of pumps. The method of claim 16, further comprising removing the plurality of cartridges by heating the at least one of the plurality of cartridges to room temperature by a heater placed in the vicinity of the plurality of cartridges Condensate in the at least one of the at least one. The method of claim 16, wherein the delivery property of the at least one drug comprises a drug delivery flow rate, a drug delivery amount, a treatment time, a remaining treatment amount, a drug being administered, a remaining drug to be administered, a drug to be administered, The duration of the drug, the order of the drugs to be delivered, wherein the treatment regimen comprises at least one of the administered drug and the agent, the duration of administration, and combinations thereof. The method of claim 16, further comprising controlling the blood glucose level for a period of time by using the glucose clamp technique by the processor. The method of claim 27, further comprising controlling the blood glucose level by the processor by using the glucose clamp technique to cause hypoglycemia for up to two hours. The method of claim 16, further comprising adjusting, by the plurality of pumps, the pumping of the at least one drug based on the adjusted delivery characteristics prior to the hypoglycemic treatment window induced by the hypoglycemic glucose clamp. The method of claim 16, further comprising adjusting, by the plurality of pumps, the pumping of the at least one drug based on the adjusted delivery characteristics during a hypoglycemic treatment window induced by hypoglycemic glucose clamps. A computer readable storage medium, the stored instructions, when executed by a processor, causing the computer to perform the following operations, comprising: controlling each of a plurality of pumps connected to a respective one of the plurality of cartridges, pumping according to a treatment plan Transmitting at least one drug contained in at least one of the plurality of cartridges, wherein the at least one drug comprises insulin, glucose, and at least one chemotherapeutic drug, and the plurality of cartridges are configured to contain insulin, glucose, and at least a chemotherapeutic drug; controlling a blood glucose sensor communicatively coupled to the plurality of pumps to measure a blood glucose level of the patient; adjusting a delivery characteristic of the at least one drug based on the measured blood glucose level of the patient; and controlling the The plurality of pumps adjust the pumping of the at least one drug based on the adjusted delivery characteristics. The computer readable storage medium of claim 31, wherein one of the plurality of cartridges comprises saline, the operation further comprising: controlling a mixer connected to the plurality of cartridges and the processor according to an adjustment The delivery characteristic dilutes the insulin with the saline, the glucose and the at least one chemotherapeutic drug to dilute the at least one drug, and controls the mixer to deliver the diluted drug to the patient. The computer readable storage medium of claim 31, wherein the operations further comprise reading the heart rhythm of the patient by an ECG monitoring system communicatively coupled to the processor; based on the measured blood glucose level of the patient and A heart rhythm to adjust delivery characteristics of the at least one drug; and controlling the plurality of pumps to adjust pumping of the at least one drug based on the measured blood glucose level and the heart rhythm of the patient to maintain a suitable blood glucose level. The computer readable storage medium of claim 31, wherein the operation further comprises monitoring a bad cardiac event detected by the ECG monitoring system for the patient; and instructing the plurality of pumps to change pumping insulin and / or the amount of glucose to return the patient to normal blood glucose levels. The computer readable storage medium of claim 31, wherein the operation further comprises downloading patient data from a server; controlling the plurality of pumps to adjust pumping of the at least one drug based on the patient data; The adjusted delivery characteristics are stored in a data store. The computer readable storage medium of claim 31, wherein the operation further comprises controlling a display communicatively coupled to the ECG monitoring system and the blood glucose sensor to receive from the ECG monitoring system and the blood glucose sensor The data is sent to show the current blood glucose level and ECG status. The computer readable storage medium of claim 31, wherein the operations further comprise: controlling audio communicatively coupled to the ECG monitoring system and the blood glucose sensor to be based on the ECG monitoring system and the The data received by the blood glucose sensor outputs an audio signal indicative of the current blood glucose level and ECG status. The computer readable storage medium of claim 31, wherein the operation further comprises: controlling the blood glucose level to be controlled for a period of time by using a glucose clamp technique. The computer readable storage medium of claim 38, wherein the operations further comprise: controlling to control blood glucose levels by using the glucose clamp technique to cause hypoglycemia for up to two hours. The computer readable storage medium of claim 31, wherein the operation further comprises: controlling, by the plurality of pumps, adjusting the pump based on the adjusted delivery characteristics prior to the hypoglycemic treatment window induced by the hypoglycemic glucose clamp Sending the at least one drug. The computer readable storage medium of claim 31, wherein the operation further comprises: controlling the plurality of pumps to adjust the pumping station based on the adjusted delivery characteristics prior to the hypoglycemic treatment window period induced by the hypoglycemic glucose clamp Said at least one drug.